Add-On ZIDA Sock Therapy for Overactive Bladder
Add-On Efficacy of Home-Based Transcutaneous Tibial Nerve Stimulation Via the ZIDA Control Sock in Adults With Overactive Bladder on Preexisting Stable Pharmacotherapy
Medical University of South Carolina
20 participants
Mar 1, 2026
INTERVENTIONAL
Conditions
Summary
Many people with overactive bladder (OAB) continue to experience symptoms despite pharmacologic treatment. This study evaluates the use of the ZIDA Control Sock, an FDA-cleared, noninvasive wearable device that delivers mild electrical stimulation near the ankle, as an adjunct to usual care. Adults with OAB-wet who remain symptomatic on stable medication will use the device at home once weekly for 12 weeks while continuing their prescribed therapy. The study collects clinical, patient-reported, and safety information during adjunctive device use.
Eligibility
Inclusion Criteria6
- Age ≥18 years.
- Diagnosis of OAB-wet (OAB with urgency urinary incontinence) documented by clinical diagnosis
- Baseline ≥1 UUI episode/day averaged over a 3-day diary
- Is on a stable pharmacotherapy for OAB for ≥4 weeks, with intent to remain on their medication regimen for the duration of this study
- Has the ability to complete bladder diaries, questionnaires, and attend follow-up visits
- Cognitively intact adult and able to understand study procedures and provide informed consent independently
Exclusion Criteria12
- Neurologic disease affecting bladder function, including multiple sclerosis, spinal cord injury, Parkinson's disease, or other neurogenic bladder conditions.
- Significant pelvic organ prolapses or other pelvic pathology likely to interfere with bladder emptying, neuromodulation efficacy, or study assessments in the opinion of the investigator
- Active urinary tract infection or unexplained hematuria at screening
- Clinically significant post-void residual volume above threshold (e.g., >100 mL)
- History of, failure of, or current use of neuromodulation therapies, including percutaneous or transcutaneous tibial nerve stimulation, sacral neuromodulation (InterStim), implantable tibial devices (eCoin)
- Intravesical botulinum toxin injections less than 9 months prior to entry into the study
- Pregnancy or plans to become pregnant during study participation, and women of childbearing age not using contraception. A urine pregnancy test will be performed for women of childbearing potential to confirm non-pregnant status prior to enrollment.
- Contraindications to electrical stimulation (cardiac pacemaker or implanted defibrillator without physician clearance, unhealed wounds near stimulation site, metal implants in the ankle region)
- Significant uncontrolled medical conditions, such as unstable cardiac disease, poorly controlled diabetes mellitus, severe peripheral edema, or severe peripheral neuropathy that may affect lower-limb sensation or response to stimulation in the opinion of the investigator
- Pelvic malignancy or prior pelvic radiotherapy.
- Current participation in another investigational drug or device trial, or use of an investigational therapy within the last 30 days
- Known hypersensitivity or intolerance to materials used in the ZIDA device (electrode adhesives, conductive gels)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The ZIDA Control Sock is an FDA-cleared, noninvasive wearable neuromodulation device designed for home use. The device delivers low-level electrical stimulation near the ankle to stimulate peripheral nerves involved in bladder control. In this study, the device is used as an adjunct to usual pharmacologic care.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07432659